Insider Transactions Reported by 32 Insiders of Dianthus Therapeutics, Inc. /DE/

Symbol
DNTH on Nasdaq
Location
New York, NY

Insiders trading volume in the past year

Dianthus Therapeutics, Inc. /DE/ executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Lei Meng Director $54,608,811 22 Jan 2024
Fairmount Funds Management LLC Director $42,395,456 27 Sep 2024
Third Rock Ventures IV, L.P. 10%+ Owner $36,698,448 07 Feb 2023
Leon O Moulder Jr. Director $17,240,940 23 May 2024
Jason Gardner Title: President and Chief Executive Officer, Director $11,339,448 30 Nov 2022
Marino Garcia CEO AND PRESIDENT, Director $3,235,871 -$10,016,381 -76% 16 Mar 2026
Kristen Stants Chief People Officer $243,168 30 Nov 2022
Thomas W. Beetham Title: Chief Legal Officer and Secretary $238,764 30 Nov 2022
Caren Deardorf Chief Commercial Officer $237,144 30 Nov 2022
Stephen F. Mahoney Title: Chief Financial and Operating Officer $207,168 30 Nov 2022
Alexis Borisy Director $49,200 26 Aug 2021
Edward Carr Chief Accounting Officer $0 -$3,559,495 -100% 12 Mar 2026
Ryan Savitz Evp, Cfo & Cbo $0 -$1,603,600 -100% 03 Feb 2026
Simrat Randhawa EVP, Head of R&D $0 -$10,136,356 -100% 12 Mar 2026
Simon Read Director 22 May 2025
Alison Frances Lawton Director 22 May 2025
Anne McGeorge Director 22 May 2025
Jonathan Violin Director 22 May 2025
Sujay Kango Director 04 Mar 2025
Paula Soteropoulos Director 22 May 2025
Steven J. Romano Director 22 May 2025
Adam M. Veness SVP, General Counsel and Sec. 03 Feb 2026
Daniel Thomas O Director 28 Jun 2022
Bruce Booth Director 28 Jun 2022
Michael W. Bonney Director 01 Jun 2021
Jeffrey W. Albers Director 28 Jun 2022
David Wayne Nichols Chief Technical Officer 01 Aug 2022
Lisa Olson Title: Head of Research and Chief Scientific Officer Exhibit 24.1: Power of Attorney 01 Aug 2022
David Scadden Director 28 Jun 2022
Michael Vasconcelles Director 15 Aug 2022
Jeffrey Humphrey Chief Medical Officer 01 Aug 2022
Amy L. Ronneberg Director 28 Jun 2022

Recent Insider Transactions by Companies or Individuals for Dianthus Therapeutics, Inc. /DE/

Showing up to 300 most recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
Marino Garcia DNTH Common Stock Options Exercise 65,292 65,292 16 Mar 2026 Direct
Marino Garcia DNTH Stock Option (Right to Buy) Options Exercise -99.9% -65,292 41 16 Mar 2026 Direct
Marino Garcia DNTH Common Stock Sale -100% $10,016,381 $81.49 -122,918 0 12 Mar 2026 Direct
Marino Garcia DNTH Common Stock Options Exercise 122,918 122,918 12 Mar 2026 Direct
Marino Garcia DNTH Stock Option (Right to Buy) Options Exercise -67.3% -122,918 59,741 12 Mar 2026 Direct
Edward Carr DNTH Common Stock Sale -100% $3,559,495 $81.49 -43,682 0 12 Mar 2026 Direct
Edward Carr DNTH Common Stock Options Exercise 43,682 43,682 12 Mar 2026 Direct
Edward Carr DNTH Stock Option (Right to Buy) Options Exercise -50.7% -43,682 42,500 12 Mar 2026 Direct
Simrat Randhawa DNTH Common Stock Sale -100% $2,756,468 $81.48 -33,830 0 12 Mar 2026 Direct
Simrat Randhawa DNTH Common Stock Options Exercise 33,830 33,830 12 Mar 2026 Direct
Simrat Randhawa DNTH Stock Option (Right to Buy) Options Exercise -89.4% -33,830 3,998 12 Mar 2026 Direct
Ryan Savitz DNTH Stock Option (Right to Buy) Award 150,000 150,000 03 Feb 2026 Direct
Simrat Randhawa DNTH Stock Option (Right to Buy) Award 150,000 150,000 03 Feb 2026 Direct
Adam M. Veness DNTH Stock Option (Right to Buy) Award 100,000 100,000 03 Feb 2026 Direct
Marino Garcia DNTH Stock Option (Right to Buy) Award 355,000 355,000 03 Feb 2026 Direct
Edward Carr DNTH Stock Option (Right to Buy) Award 55,000 55,000 03 Feb 2026 Direct
Ryan Savitz DNTH Common Stock Sale -100% $903,600 $45.18 -20,000 0 04 Dec 2025 Direct
Ryan Savitz DNTH Common Stock Options Exercise 20,000 20,000 04 Dec 2025 Direct
Ryan Savitz DNTH Stock Option (Right to Buy) Options Exercise 30.9% 20,000 84,766 04 Dec 2025 Direct
Simrat Randhawa DNTH Common Stock Sale -96.5% $4,158,442 $38.14 -109,031 4,000 14 Nov 2025 Direct
Simrat Randhawa DNTH Common Stock Options Exercise 2725.8% 109,031 113,031 14 Nov 2025 Direct
Simrat Randhawa DNTH Stock Option (Right to Buy) Options Exercise -63.6% -109,031 62,506 14 Nov 2025 Direct
Simrat Randhawa DNTH Common Stock Sale -95.6% $3,221,445 $36.81 -87,507 4,000 13 Nov 2025 Direct
Simrat Randhawa DNTH Common Stock Options Exercise 2187.7% 87,507 91,507 13 Nov 2025 Direct
Simrat Randhawa DNTH Stock Option (Right to Buy) Options Exercise -87.9% -87,507 11,996 13 Nov 2025 Direct
Marino Garcia DNTH Stock Option (Right to Buy) Award 120,000 120,000 30 Sep 2025 Direct
Ryan Savitz DNTH Stock Option (Right to Buy) Award 60,000 60,000 23 Sep 2025 Direct
Simrat Randhawa DNTH Stock Option (Right to Buy) Award 60,000 60,000 23 Sep 2025 Direct
Ryan Savitz DNTH Common Stock Sale -100% $700,000 $35.00 -20,000 0 09 Sep 2025 Direct
Ryan Savitz DNTH Common Stock Options Exercise 20,000 20,000 09 Sep 2025 Direct
Ryan Savitz DNTH Stock Option (Right to Buy) Options Exercise 23.6% 20,000 104,766 09 Sep 2025 Direct
Jonathan Violin DNTH Stock Option (Right to Buy) Award 12,500 12,500 22 May 2025 Direct
Paula Soteropoulos DNTH Stock Option (Right to Buy) Award 12,500 12,500 22 May 2025 Direct
Steven J. Romano DNTH Stock Option (Right to Buy) Award 12,500 12,500 22 May 2025 Direct
Anne McGeorge DNTH Stock Option (Right to Buy) Award 12,500 12,500 22 May 2025 Direct
Alison Frances Lawton DNTH Stock Option (Right to Buy) Award 12,500 12,500 22 May 2025 Direct
Simon Read DNTH Stock Option (Right to Buy) Award 25,000 25,000 22 May 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.